Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity

US7879838B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Pharmacopeia Drug Discovery, Inc. · US

Inventors

• Qingbei Zeng · Shanghai, CN
• De-Yi Yang · Morristown, US
• Stuart B. Rosenblum · West Orange, US
• Michael K. C. Wong · New Brunswick, US
• Gopinadhan N. Anilkumar · Edison, US
• Seong Heon Kim · Livingston, US
• Wensheng Yu · Edison, US
• Joseph A. Kozlowski · Princeton, US
• Neng-Yang Shih · Lexington, US
• Brian F. McGuinness · Plainsboro, US
• Lisa Guise Zawacki · Yardley, US
• Doublas W. Hobbs · Yardley, US

Key dates

• Filing date: Feb 14, 2006
• Grant date: Feb 1, 2011
• Expiry date: Mar 3, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.